GluBio Therapeutics
About Us
GluBio Therapeutics Inc. ("GluBio") is a biotechnology company dedicated to the discovery and development of novel molecular glue degraders (MGDs), with a mission to address unmet clinical needs across oncology, autoimmune diseases, and genetic disorders, etc. The founders and core team members possess extensive experience in molecular glue drug discovery and management. Since its establishment in March 2021, the company has secured funding from top-tier investors, including Hillhouse Capital, Qiming Venture Partners, Lilly Asia Ventures, Kaitai Capital, Legend Capital, K2VC, and E Fund Capital.
As a leader in the field, GluBio leverages its proprietary Glue Degrader Discovery (GDD©) platform to drive systematic innovation. The company has built an integrated R&D engine comprising an innovative target identification and validation, a multi-dimensional protein degradation screening, a rational molecular glue design, and a diverse proprietary compound library.
GluBio focuses on developing molecular glue degraders with “first-in-class” and “best-in-class” potential. All pipeline programs are independently developed and protected by global intellectual property rights. Notably, two novel molecular glue degraders, GLB-001 and GLB-002, have already entered clinical-stage studies both in the U.S. and China.
Our Milestones
Meet the Founders
Dr. Gang Lu, Founder of GluBio, oversees the company’s overall strategic planning, financial management, and operations.
As an experienced molecular biologist and pharmacologist, Dr. Lu has over 10 years of experience in drug development in the field of targeted protein degradation. Prior to founding GluBio, he led the discovery, IND submissions, and clinical translation of multiple molecular glue degraders at Bristol Myers Squibb/Celgene.
Dr. Lu received his Ph.D. in Physiology from the University of California, Los Angeles. He also holds a Master’s degree in Genetics and a Bachelor’s degree in Microbiology from Fudan University. During his postdoctoral research at the Dana-Farber Cancer Institute & The Howard Hughes Medical Institute, he trained under Dr. William G. Kaelin, Jr., a recipient of the 2019 Nobel Prize in Physiology or Medicine. Dr. Lu was the first in the world to discover and elucidate the molecular glue mechanism of the immunomodulatory drug (IMiD) lenalidomide, publishing his findings in Science in 2014.
Dr. Liqiang Fu, Co-Founder of GluBio, responsible for leading the company’s early-stage R&D management and operations in China.
Dr. Fu, an experienced medicinal chemist, has over 20 years of drug discovery experience, including nearly 10 years in the field of targeted protein degradation. Prior to founding GluBio, he held positions at AbbVie and Johnson & Johnson, where he led the drug discovery efforts for multiple novel projects. During his tenure at Johnson & Johnson, he played a leading role in establishing chemistry platforms for targeted protein degradation, including PROTAC Toolbox and molecular glue compound library.
Dr. Fu received his Ph.D. in Medicinal Chemistry from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and then completed post-doctoral fellowship in Medicinal Chemistry and Chemical Biology at the University of Kansas.
